Golidocitinib Combined With P-GemOx Plus PD-1 Inhibitor Versus P-GemOx Plus PD-1 Inhibitor in First-Line Newly Diagnosed Advanced or Non-Nasal Extranodal NK/T-Cell Lymphoma

NCT07385989 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Extranodal NK/T-cell Lymphoma

Interventions

DRUG: Golidocitinib in combination with P-GEMOX and PD-1 inhibitor
DRUG: PD-1 inhibitor in combination with P-GEMOX

Sponsor

WEI XU